Oxurion

Oxurion EBITDA per Employee

The EBITDA per Employee of Oxurion (OXUR.BR) as of Oct 16, 2026 is 6,805.19 EUR. In the previous year, EBITDA per Employee was -152,129.87 EUR — a change of -104.47% (higher).

EBITDA per Employee

6,805.19EUR

YoY

-104.47%

Last updated:

EBITDA per Employee of Oxurion is 2024 6,805.19 EUR. EBITDA per Employee of Oxurion was 2023 -152,129.87 EUR. It decreases by -104.47% higher compared to the previous year.

The Oxurion EBITDA per Employee history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBITDA per Employee
Date
EBITDA per Employee
Jan 1, 2017
351,896.10 EUR
Jan 1, 2018
-462,519.48 EUR
Jan 1, 2019
-422,207.79 EUR
Jan 1, 2020
-355,662.34 EUR
Jan 1, 2021
-346,636.36 EUR
Jan 1, 2022
-280,402.60 EUR
Jan 1, 2023
-152,129.87 EUR
Jan 1, 2024
6,805.19 EUR
The Oxurion EBITDA per Employee history
YEAREBITDA per EmployeeYoY
6,805.19EUR-104.47%
-152,129.87EUR-45.75%
-280,402.60EUR-19.11%
-346,636.36EUR-2.54%
-355,662.34EUR-15.76%
-422,207.79EUR-8.72%
-462,519.48EUR-231.44%
351,896.10EUR-201.98%
-345,064.94EUR-14.10%
-401,688.31EUR-30.65%
-579,220.78EUR—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Oxurion Stock analysis

What does Oxurion do? Oxurion NV is a biotechnology company based in Heverlee, Belgium, operating within the healthcare sector. The company has 77 employees and went public on July 7, 2006. Oxurion focuses on developing and commercializing treatments for vitreoretinal diseases. Its lead product, JETREA (ocriplasmin), received U.S. Food and Drug Administration approval for the treatment of symptomatic vitreomacular adhesion (VMA) and was launched in January 2013. The company collaborates with Alcon, a division of Novartis, for the commercialization of JETREA outside the United States. In Europe, JETREA is approved for the treatment of vitreomacular traction (VMT), including cases associated with macular holes of 400 microns or smaller, with launches in the United Kingdom and Germany. Oxurion is also researching anti-PIGF (Placental Growth Factor), known as TB-403, for potential use in ophthalmic and oncology treatments. The company maintains operations in Belgium, the United States, and Ireland, with its headquarters in Heverlee, Vlaams-Brabant. Oxurion's website is www.oxurion.com. Oxurion is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Oxurion stock

EBITDA per Employee of Oxurion is 6,805.19 EUR in 2024.

EBITDA per Employee of Oxurion changed from -152,129.87 EUR to 6,805.19 EUR, representing a -104.47% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of EBITDA per Employee Oxurion since 2006 – with annual values, charts, and detailed analysis.

EBITDA per employee measures operating cash earnings generated per employee, showing workforce productivity before depreciation and financing effects.

EBITDA per Employee's EUR is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track EBITDA per Employee's Oxurion historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Workforce — Oxurion

All Key Metrics — Oxurion